Privium Fund Management B.V. Acquires 25,100 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Key Points

• Privium Fund Management B.V. increased its stake in CRISPR Therapeutics AG by 71.7%, acquiring an additional 25,100 shares, bringing their total ownership to 60,097 shares worth approximately $2,045,000.
• Several institutional investors have also boosted their holdings in CRISPR, with PNC Financial Services increasing by 31.8% and US Bancorp DE by 153.3% during the first quarter.
• Although CRISPR Therapeutics reported a quarterly loss of ($1.58) EPS, their revenue increased by 71.6% year-over-year, with analysts predicting a consensus rating of "Hold" and an average price target of $71.31.

Privium Fund Management B.V. boosted its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 71.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 60,097 shares of the company's stock after purchasing an additional 25,100 shares during the quarter. CRISPR Therapeutics accounts for approximately 0.5% of Privium Fund Management B.V.'s holdings, making the stock its 24th biggest position. Privium Fund Management B.V. owned 0.07% of CRISPR Therapeutics worth $2,045,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Wood Tarver Financial Group LLC acquired a new position in shares of CRISPR Therapeutics during the fourth quarter valued at about $30,000. Ameriflex Group Inc. bought a new position in CRISPR Therapeutics during the fourth quarter valued at about $36,000. NBC Securities Inc. raised its holdings in CRISPR Therapeutics by 156,300.0% in the 1st quarter. NBC Securities Inc. now owns 1,564 shares of the company's stock valued at $53,000 after acquiring an additional 1,563 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of CRISPR Therapeutics in the 4th quarter worth approximately $71,000. Finally, US Bancorp DE lifted its position in shares of CRISPR Therapeutics by 153.3% in the 1st quarter. US Bancorp DE now owns 3,063 shares of the company's stock worth $104,000 after acquiring an additional 1,854 shares during the period. 69.20% of the stock is owned by institutional investors.

CRISPR Therapeutics Trading Up 1.4%

Shares of CRISPR Therapeutics stock traded up $0.78 during midday trading on Wednesday, reaching $56.37. The company had a trading volume of 2,231,763 shares, compared to its average volume of 2,594,475. The stock has a fifty day simple moving average of $50.45 and a 200 day simple moving average of $43.63. CRISPR Therapeutics AG has a 1-year low of $30.04 and a 1-year high of $71.13. The company has a market capitalization of $4.87 billion, a price-to-earnings ratio of -10.38 and a beta of 1.80.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its earnings results on Monday, August 4th. The company reported ($1.29) EPS for the quarter, beating the consensus estimate of ($1.47) by $0.18. CRISPR Therapeutics had a negative return on equity of 19.55% and a negative net margin of 1,229.43%. The company had revenue of $0.89 million during the quarter, compared to analysts' expectations of $6.44 million. During the same period last year, the firm earned ($1.49) EPS. The business's revenue for the quarter was up 72.5% on a year-over-year basis. Sell-side analysts expect that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Insider Activity

In other CRISPR Therapeutics news, Director Simeon George purchased 989,812 shares of the stock in a transaction dated Wednesday, July 16th. The stock was bought at an average price of $52.03 per share, for a total transaction of $51,499,918.36. Following the transaction, the director directly owned 1,730,179 shares in the company, valued at $90,021,213.37. This represents a 133.69% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Naimish Patel sold 3,932 shares of the stock in a transaction that occurred on Thursday, May 29th. The shares were sold at an average price of $35.94, for a total transaction of $141,316.08. Following the completion of the transaction, the insider owned 6,068 shares in the company, valued at $218,083.92. This represents a 39.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 4.10% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently commented on CRSP shares. JMP Securities restated a "market outperform" rating and issued a $86.00 target price on shares of CRISPR Therapeutics in a research note on Friday, June 27th. HC Wainwright restated a "buy" rating and issued a $65.00 price objective on shares of CRISPR Therapeutics in a research note on Friday, June 27th. Chardan Capital reaffirmed a "buy" rating and set a $82.00 price objective on shares of CRISPR Therapeutics in a report on Tuesday. Needham & Company LLC reiterated a "buy" rating and set a $81.00 target price on shares of CRISPR Therapeutics in a research report on Tuesday, July 8th. Finally, Royal Bank Of Canada increased their price target on shares of CRISPR Therapeutics from $38.00 to $42.00 and gave the stock a "sector perform" rating in a research report on Tuesday. Two research analysts have rated the stock with a sell rating, six have given a hold rating and nine have given a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $70.60.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.